HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.

AbstractWe report herein the case of a 40-year-old man with grade II invasive ductal carcinoma of the breast (pT1, pN0, M0: stage I) in whom a recurrence developed shortly after completion of a 2-year course of tamoxifen and 5-fluorouracil therapy following a mastectomy. Although the metastatic tumor was estrogen receptor-positive, hormone therapy combined with chemotherapy had no significant effect on tumor growth, and the patient died from disseminated tumors 2 years 6 months after completion of the adjuvant therapy. It is noteworthy that the circulating estradiol level increased from 18.0 to 892.3 pg/ml during the period of tumor progression and dissemination. We interpret these findings as an indication of high aromatase activity in the metastatic tumors. We suggest that extending tamoxifen treatment to 5 years or longer be recommended for the standard adjuvant hormone therapy of male breast cancer to prevent the early recurrence of hormone-responsive disease.
AuthorsH Takei, Y Iino, J Horiguchi, M Maemura, Y Koibuchi, T Yokoe, Y Morishita, V C Jordan (Affiliation: Second Department of Surgery, Gunma University School of Medicine, Maebashi, Japan.)
JournalSurgery today (Surg Today) Vol. 31 Issue 2 Pg. 149-51 ( 2001) ISSN: 0941-1291 [Print] Japan
PMID11291709 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Hormonal
  • Tamoxifen
  • Estradiol
  • Fluorouracil
Topics
  • Adult
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Antineoplastic Agents, Hormonal (pharmacology, therapeutic use)
  • Breast Neoplasms, Male (drug therapy, pathology, surgery)
  • Carcinoma, Ductal, Breast (drug therapy, pathology, surgery)
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm
  • Drug Therapy, Combination
  • Estradiol (blood)
  • Fatal Outcome
  • Fluorouracil (therapeutic use)
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Tamoxifen (pharmacology, therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD